{"id":"W3006286575","doi":"10.1002/hon.2723","title":"Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Carfilzomib; Ibrutinib; Medicine; Dexamethasone; Refractory (planetary science); Multiple myeloma; Oncology; Internal medicine; Lenalidomide; Leukemia; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005692292,0.001859521,0.002818902,0.0006432018,0.0005878726,0.00126684,0.0007497036,0.001195094,0.001961601],"category_scores_gemma":[0.002163246,0.0007521571,0.002805503,0.0005827008,0.0007942197,0.0006859779,0.0004920168,0.002626922,0.0005922091],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001322784,"about_ca_system_score_gemma":0.001949471,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001086845,"about_ca_topic_score_gemma":0.002639574,"domain_scores_codex":[0.9974064,0.001717364,0.0001220773,0.000272217,0.0001874583,0.000294335],"domain_scores_gemma":[0.9984138,0.0003580541,0.0002898162,0.0001493859,0.0001299096,0.0006590699],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7700758,0.06285124,0.02952061,0.0006691577,0.005336222,0.0006565893,0.0004115612,0.003150275,0.05321684,0.0002433747,0.003531824,0.07033643],"study_design_scores_gemma":[0.413271,0.5283682,0.04758287,0.00003857765,0.001761974,0.000334761,0.00007539304,0.001239598,0.003709792,0.0001476583,0.003421671,0.00004845569],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99098,0.001784762,0.0006051637,0.0005867054,0.00009046978,0.003232297,0.001581554,0.00007042301,0.001068699],"genre_scores_gemma":[0.9889144,0.0007677402,0.002215012,0.0009698432,0.0001927129,0.002238723,0.003632171,0.00003144017,0.001037937],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005692292,"threshold_uncertainty_score":0.03010404,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06631480899877269,"score_gpt":0.3511896877632336,"score_spread":0.2848748787644609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}